China science, technology news summary -- May 5 - Buz & Tech News sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.
2021-05-05 08:35:20 GMT2021-05-05 16:35:20(Beijing Time) Xinhua English
SHANGHAI, May 5 (Xinhua) Shanghai has accelerated its pace of immunological research to take the lead in boosting China s innovation in the prevention and treatment of immunological diseases.
The newly launched Shanghai Immune Therapy Institute is the latest example of the city s efforts to build world-class immunology research hubs. Established at the Renji Hospital under the Shanghai Jiao Tong University School of Medicine, the institute will focus on three research areas: tumor immunotherapy, chronic inflammatory diseases and transplantation immunology, and infectious diseases and vaccines.
The institute aims to become a frontier research and development center with global talent by 2025, and one of the world s leading institutes in the fields of new drug targets, new mechanisms, antibody-drug development, immunotherapy and other major immune-related diseases by 2035, according to a hospital statem
Cd86), were down-regulated in
Mettl3-deficient cells (Fig. 1G), suggesting that METTL3 has a critical function in controlling the innate immune response of Raw 264.7 macrophages.
To further confirm the biological role of the m
6A modification in macrophages,
Mettl3 conditional KO (CKO) mice were generated by crossing
Mettl3
flox/flox mice with mice expressing Cre recombinase under the control of lysozyme 2 promoter (
Lyzm-Cre). We have documented the loss of both the METTL3 protein and the overall m
6A modification in bone marrow–derived macrophages (BMDMs) from
Mettl3
flox/flox;
Lyzm-Cre mice (fig. S1I). No differences in the frequency of major immune cell populations were observed between
Published: Apr 12, 2021
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after fail
Medical experts call for better kidney care By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2021-03-10 11:27 Share CLOSE Leading medical experts call for a higher awareness of chronic kidney diseases, which afflict more than 150 million people in China, ahead of the World Kidney Day on March 11. [Photo by Zhou Wenting/chinadaily.com.cn]
Medical experts have called for a higher awareness of chronic kidney diseases, especially the type that afflicts young and middle-aged people, ahead of World Kidney Day on March 11.
According to World Health Organization figures released in December, kidney diseases have become one of the top 10 causes of death in the world. In China, more than 150 million people suffer from chronic kidney diseases.